Ensuring Timely Access to Terbium-161 Therapy at FMRI
By Dr. Ishita B. Sen
Senior Director – Nuclear Oncology & Molecular Imaging
Fortis Memorial Research Institute (FMRI), Gurugram
In the realm of cancer treatment, timing is paramount. Delays can compromise outcomes, especially in aggressive or advanced-stage diseases. At FMRI, we recognize the critical importance of timely therapy, particularly when it involves cutting-edge treatments like Terbium-161 (Tb-161) radioligand therapy.
Reliable Supply Chain for Tb-161
Tb-161 is produced through neutron irradiation of enriched Gadolinium-160 (¹⁶⁰Gd) in nuclear reactors. TerThera, based in the Netherlands, is a leading global supplier of this isotope. They have established agreements with facilities like the High Flux Reactor in Petten to ensure a consistent production pipeline.
Source: https://www.advancingnuclearmedicinetherapy.com/news/nrg-and-terthera-sign-irradiation-agreement-to-ensure-the-continuous-supply-of-terbium-161
At FMRI, we have secured a dependable supply chain with TerThera, receiving Tb-161 shipments twice a month. This regularity ensures that our patients have uninterrupted access to this vital therapy, allowing for precise scheduling and minimizing treatment delays.
The Imperative of Timely Treatment
Cancer progression doesn’t pause, and neither should its treatment. Delays can lead to tumor growth, metastasis, and reduced responsiveness to therapy. Timely administration of treatments like Tb-161 is crucial for maximizing efficacy and improving patient outcomes.
Advantages of Tb-161 in Cancer Therapy
Tb-161 emits beta particles along with Auger and conversion electrons, delivering a potent dose of radiation directly to cancer cells while sparing surrounding healthy tissue. This makes it particularly effective against microscopic tumor clusters and metastases.
Source: https://jnm.snmjournals.org/content/65/supplement_2/2430
Clinical studies have shown that Tb-161 can deliver approximately 40% more radiation to tumors per unit than Lutetium-177, potentially leading to better tumor control with fewer side effects.
Source: https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-023-00589-w
Structured Treatment Protocols at FMRI
Our Tb-161 therapy protocol involves 4 to 6 cycles, spaced 8 to 12 weeks apart, tailored to each patient’s response and tolerance. This structured approach, combined with our reliable isotope supply, ensures that patients receive their treatments on schedule, optimizing the therapy’s effectiveness.
Commitment to Patient-Centric Care
At FMRI, our focus is on delivering timely, effective, and personalized cancer care. With our consistent access to Tb-161 and a dedicated multidisciplinary team, we are well-equipped to provide this advanced therapy to patients who can benefit from it.
Need a Second Opinion?
If you or a loved one is exploring Terbium-161 therapy, we welcome you to share your medical history, diagnostic imaging, and test results with
Dr. Ishita B. Sen
via email: info@nuclearmedicinetherapy.in
to receive a quick second opinion from our expert team.